Justin Schreiber Sells 50,000 Shares of LifeMD, Inc. (NASDAQ:LFMD) Stock

LifeMD, Inc. (NASDAQ:LFMD) CEO Justin Schreiber sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $7.55, for a total transaction of $377,500.00. Following the completion of the transaction, the chief executive officer now owns 2,653,715 shares in the company, valued at approximately $20,035,548.25. This represents a 1.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Justin Schreiber also recently made the following trade(s):

• On Thursday, January 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The shares were sold at an average price of $5.19, for a total transaction of $129,750.00.
• On Monday, December 2nd, Justin Schreiber sold 25,000 shares of LifeMD stock. The stock was sold at an average price of $6.52, for a total value of $163,000.00.

LifeMD Stock Performance

Shares of LFMD stock opened at $5.46 on Friday. The firm has a fifty day moving average of $5.69 and a 200-day moving average of $5.40. The stock has a market cap of $236.47 million, a price-to-earnings ratio of -8.53 and a beta of 1.50. LifeMD, Inc. has a 52-week low of $3.99 and a 52-week high of $12.88.

Institutional Trading of LifeMD

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LFMD. ProShare Advisors LLC bought a new position in LifeMD during the fourth quarter worth about $51,000. Oxford Asset Management LLP bought a new position in shares of LifeMD during the 4th quarter worth approximately $52,000. Balyasny Asset Management L.P. acquired a new stake in LifeMD in the 4th quarter valued at $52,000. Intech Investment Management LLC acquired a new stake in LifeMD in the 3rd quarter valued at $54,000. Finally, AXQ Capital LP bought a new stake in LifeMD in the fourth quarter valued at $57,000. Institutional investors own 35.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on LFMD shares. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of LifeMD in a research note on Monday, November 11th. Mizuho started coverage on LifeMD in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 price target for the company. KeyCorp dropped their price objective on LifeMD from $10.00 to $7.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Finally, Lake Street Capital initiated coverage on shares of LifeMD in a research note on Tuesday, December 10th. They issued a “buy” rating and a $12.00 target price for the company. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.14.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.